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Abstract
Purpose: This work aims to introduce a method to quantify and assess the differences in monitor unites MUs when changing to
new dose calculation software that uses a different algorithm, and to evaluate the need and extent of adjustment of the pre-
scribed dose to maintain the same clinical results. Methods: Doses were calculated using two classical algorithms based on the
Pencil Beam Convolution PBC model, using 6 patients presenting lung cancers. For each patient, 3 treatment plans were gener-
ated: Plan 1 was calculated using reference algorithm PBC without heterogeneity correction, Plan 2 was calculated using test
algorithm with heterogeneity correction, and in plan 3 the dose was recalculated using test algorithm and monitor unites MUs
obtained from plan 1 as input. To assess the differences in the calculated MUs, isocenter dose, and spatial dose distributions us-
ing a gamma index were compared. Statistical analysis was based on a Wilcoxon signed rank test. Results: The test algorithm in
plan 2 calculated significantly less MUs than reference algorithm in plan 1 by on average 5%, (p < 0.001). We also found under-
estimating dose for target volumes using 3D gamma index analysis. In this example, in order to obtain the same clinical out-
comes with the two algorithms the prescribed dose should be adjusted by 5%. Conclusion: This method provides a quantitative
evaluation of the differences between two dose calculation algorithms and the consequences on the prescribed dose. It could be
used to adjust the prescribed dose when changing calculation software to maintain the same clinical results as obtained with the
former software. In particular, the gamma evaluation could be applied to any situation where changes in the dose calculation
occur in radiotherapy.
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Introduction
Treatment planning in radiotherapy involves the calculation
of Monitor Units (MUs), which describe the real quantity of
ionizing radiation delivered to the patient. Therefore, the
algorithm integrated in the Treatment Planning System (TPS)
and used to compute the dose distribution in the patient is
critical. To be suitable for clinical use, these algorithms must
calculate the dose as accurately and fast as possible. Successive
generations of algorithms have been developed with an in-
creasingly improved accuracy. When considering a change
from one algorithm to another, it is necessary to verify that
the new algorithm will not introduce unexpected results in
practice. A major difficulty when implementing a new algo-
rithm is to predict any necessary modification of the pre-
scribed dose to be made by the clinician, so as to maintain the
same clinical results in terms of tumor control and risk of
complications. Several studies have compared the perfor-
mance of commercial algorithms and evaluated the dose
calculation algorithms in external photon beam therapy for
common treatment sites.1, 2, 3, 4 In these studies dose data such
as depth dose curve, profiles and isodose were compared.
They reported large dose differences, recommended a careful
analysis before introducing new algorithms in daily practice
and pointed out the need for discussion between physicists
and oncologists to fully understand the effects and potential
consequences of such changes. As yet, it is unclear when and
how increase or decrease the change in TPS justifies adjusting
the prescribed dose. In this work we studied how to manage
the implementation of new calculation algorithms in radio-
therapy and to help decide when and how to alter the dose
prescription. The new algorithm has been first validated by
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measurements in phantoms in the department according to
the international recommendations. Then comes the step of
comparison with the former algorithm to enlighten and
quantify which adaptation of the prescriptions could be nec-
essary. The present paper is devoted to this further step.
Methods and Materials
Dose calculation algorithm
In this study, the improvement of the heterogeneity calcula-
tion was used as an example of a software change. The dose
calculation was performed using the widely available Pencil
Beam Convolution algorithm (PBC) integrated in the Eclipse®
TPS (Version 8.1; Varian Medical Systems). The Eclipse® TPS
contains two algorithms based on PBC 5, 6, 7:
 Reference algorithm: calculates the dose using PBC
without heterogeneity correction.
 Test algorithm: calculates the dose taking into ac-
count the 1D heterogeneity using a correction fac-
tor based on a modified Batho’s method (PBC-MB).
Batho’s method takes into account the real density of the
tissues instead of considering them all as water equivalent.
The PBC-MB algorithm calculates the dose in a heterogene-
ous situation by applying correction factors to the dose dis-
tribution first obtained considering water equivalent tissues.
The correction factor was determined by ray tracing from the
primary radiation source to the point of interest. Several
studies have discussed the limitations of the Batho’s method
for inhomogeneity corrections.8, 9, 10
The algorithms used in this study were not chosen to perform
any intrinsic technical dosimetric evaluation, but to challenge
and validate this method. Therefore we used two algorithms
currently used in our department to challenge and validate
this method.
Clinical cases
The method described in this study has been applied to lung
cancer using 6 patients. The Planning Target Volumes (PTVs)
were treated with 18MV photon beams. Radiation oncologists
delineated the anatomic borders of target structures and or-
gans at risk (OARs). The PTVs were defined according to the
recommendations of ICRU Reports 50 and 62.11, 12
Treatment planning
For each patient, 3 treatment plans were generated using
exactly the same configuration of beams, collimator and ac-
cessories, making the change in MUs a reliable parameter to
compare dosimetric calculations. The treatment plans were
3D conformal plans using multi-leaf collimators (MLC). Plan
1 was calculated using reference algorithm. Plan 2 was cal-
culated using test algorithm. In plan 3, the dose distribution
was calculated using the test algorithm, but introducing the
MUs obtained from reference algorithm. This means plan 3
was a visualization of the dose distribution of the treatment
obtained with the new algorithm, but planned using the MUs
of the previous algorithm (reference). Thus, plan 3 shows
how an old plan looks in the new system. In all plans, the dose
was prescribed at a single reference point as recommended by
ICRU. Plan 1 was the reference plan and was the one used to
actually treat the patients. The reference treatment plans
were designed according to the clinical experience of the
department and ICRU recommendations. For the PTVs, 95%
of the prescribed dose encompassed the volume and the
maximum dose within the PTVs was under 107% of the pre-
scribed dose. For OARs, the recommended dose constraints
were respected in plan 1. The choice of plan 1 as the reference
plan is based on the accepted results which have been ob-
tained over many years of clinical experience. In all radiation
oncology departments the dose has been calculated for a long
time without heterogeneity correction using Clarkson or PBC
algorithms and oncologists have gained experience in pre-
scribing and in prescription adjustment using theses algo-
rithms. Furthermore, the tolerated doses for OARs are also
based on algorithms that do not have a heterogeneity correc-
tion. Principally for these reasons the reference plan (Plan 1)
used in this study was the method traditionally used in our
department without heterogeneity correction using PBC.
Treatment plan evaluation
Delivered dose
For each patient, the MUs calculated for each field using plan
1 and plan 2 were compared. The MUs calculated in plan 1
were taken as the reference values. The difference in per-
centage was calculated as:
ΔMU (%) = (MUplan2 - MUplan1) × 100/MUplan1 (1)
The positives values mean that the MUs for plan 2 using test
algorithm were higher than the MUs for plan 1 using refer-
ence algorithm (MUplan2> MUplan1) and negative values would
mean the opposite (MUplan2 < MUplan1).
The isocenter dose calculated in plan 3 was compared to that
prescribed by the oncologists in plan 1. The difference in
percentage was:
ΔDose (%) = (Doseplan3 - Doseplan1) × 100 / Doseplan1 (2)
The positives values mean that the calculated dose at the
isocenter using MUs from plan 1 was higher than the pre-
scribed dose by the oncologists (Doseplan3 > Doseplan1) and
negative values would mean the opposite (Doseplan3 < Dose-
plan1).
Dose distribution in 2D and 3D
The gamma index () was introduced by Low et al. to compare
and evaluate the dose distribution in 2D and 3D. Later,
gamma volume histograms were introduced by Spezi et al. to
compare IMRT treatment plans.13, 14 The  combine’s two
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criteria: the Distance to Agreement (DTA) in millimeters and
the dose difference, in percentage, between evaluated and
reference points. An ellipse is used to determine the ac-
ceptance region. A  ≤ 1 represents fulfillment of the criteria.
In our study  was used to compare the dose calculation al-
gorithms.  index is particularly useful to making an overall
comparison of all fields used in each treatment plan. A  index
in 2D and 3D was used to compare the spatial dose distribu-
tion for all structures including PTVs and OARs. Superposi-
tion of the  map with the CT-scan introduced the anatomic
information. We could then see the healthy lung and spinal
cord located around the PTVs.
2D Gamma
The 2D  is based on a comparison of planar dose distribu-
tions. The DICOM images for each patient were exported
from Eclipse® TPS to RIT-113® (Dosimetry System Version
5.2) for both plan 1 and plan 2 including the dose distribu-
tions. The matrix of doses was aligned with the treatment
isocenter. The dimensions were 20 × 20 cm² and the resolu-
tion was 0.39 mm. The analysis was displayed using a  map
and gamma pixels histogram which indicates the fraction of
pixels with  index equal or lower than a specific value.
3D Gamma
The DICOM images for each patient were exported from
Eclipse® TPS for plan 1 and plan 2 including both the tumor
volumes and OARs. The evaluation was displayed using 
maps and cumulative Gamma Voxels Histograms (GVHs).15, 16
To generate  maps, the voxels outside the patient (~ 0 Gy)
were ignored and the voxels with lower doses (10 %) were
also disregarded for the quantitative analysis (khaki pixels in
the gamma map). If the difference between the two algo-
rithms induced  > 1, this will show either an under or over
estimating dosage. In order to discriminate an over from an
under estimated dose, a sign was attributed to absolute values
of gamma:
 a positive sign shows an over dosage indicating that
the calculated dose using test algorithm (Dt) is
higher than the calculated dose using reference
algorithm Dr, (Dt ≥ Dr)
 a negative sign shows under dosage indicating that
the calculated dose using test algorithm is lower
than the calculated dose using reference algorithm
(Dt < Dr).
The  map resulting from 3D gamma was as color coded into
three regions: green indicates gamma values ranging from -1
to +1; red shows the gamma values ranging from +1 to +2; and
blue shows the gamma values ranging from -1 to -2. Thus the
red and blue zones in the 3D gamma map show respectively
over and under estimated doses resulting from test algorithm
compared with reference algorithm. Then, the results of 
map were exploited for quantitative analysis by generating
GVHs. The cumulative GVHs show the volume ratios with an
 equal or lower than a given value.
Tolerance and action levels
In the present work, the  criteria were set at 3% for the dose
and 3 mm for DTA. The (3%, 3 mm) is the common tolerance
threshold of the  index in IMRT when comparing the
measured dose with calculated dose. For the 2D gamma
evaluation we considered that the plan 1 and plan 2 were
similar if 95% of pixels had a  ≤ 1. For 3D gamma evaluation
we considered that there was no dose difference between the
test and reference algorithms for plan 1 and plan 2 if 95% of
voxels had  between -1 and +1.
Statistical analysis
Wilcoxon signed rank test was used to calculate p-value using
an alpha error of 5%. The software programming language R
was used for statistical computing.17 The mean values and
standard deviations (SD) were used to calculate the Confi-
dence Limit (CL) for the results according to the equation
proposed by Palta et al. 18:
CL = |mean deviation| + 1.96 × SD              (3)
This analysis was performed including all fields for ΔMUwith
(n = 59), the whole group of patients (n = 6) for ΔDose and
gamma index in order to make a generalized decision.
Medical decision
We expected that the medical decision would depend on
whether the difference between both MUs and gamma in-
dexes were significant or not. The gamma index provides an
overall comparison that makes a decision easier than field by
field comparison with MUs. The gamma evaluation shows
any under or over dosage for one algorithm compared to
another. If the new algorithm provides a statistically signifi-
cant difference, the oncologist can/should adjust his pre-
scription of dose. If the new algorithm calculates lower MUs,
the associated risk is an under dosage of the PTVs. So, it could
be suggested that the oncologist must increase the prescribed
dose. In contrast, if the new algorithm calculates higher MUs,
the associated risk is an over-dosage of OARs and it could be
suggested that the oncologist must decrease the prescribed
dose.
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FIG. 1: Summary of the method for making a medical decision.
FIG. 2: The number of beam as a function of percentage difference in MUs for 59 fields. The differences for MUs were calculated according to
Equation 1. We note that using test algorithm in plan 2 compared to reference algorithm in plan 1, the MUs were not changed for 13 fields, but
the MUs were lower for 43 fields and higher for 3 fields.
The principle of the method described below is illustrated in
Figure 1. In a first step the difference in MUs, the dose at
isocenter and p-value must be calculated. This allows the
transfer of actual delivered dose (instead of the prescribed
dose) from one treatment calculation to another, providing
other variables remain unchanged. In this way the conse-
quences of a change in the method of calculation can be
readily made clear to the radiation oncologist. If the differ-
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ence in MUs is more than 1% with p-value < 5%, the 2D
gamma will be quickly proceeded as a second possibility to
compare the dose distribution. The 2D global gamma index
shows the dose difference in a plane. Using a 2D gamma
evaluation the gamma map and the gamma pixel histogram
are calculated. If there is any fraction of the pixels with
gamma >1 located in the region of interest (PTVs or OARs),
then a 3D gamma requiring much longer computing time
must be performed to estimate the under and over dosage
resulting from one algorithm compared to the other. The
overall 3D gamma index gives the dose difference in the
volumes. Gamma maps provide a useful tool for interpreting
gamma distribution and the location of the difference in
PTVs or OARs. Gamma values can be displayed in various
color codes in 2D or 3D gamma maps. The positive and nega-
tive difference values show the over and under estimated




The algorithm PBC-MB in plan 2 calculated significantly less
MUs than reference algorithm in plan 1 by on average 5%
(4.4 SD ; p < 0.001) with CL =13.6. Figure 2 shows the number
of the beams as a function of percentage difference in MUs
between reference and test algorithms. PBC-MB applied to
plan 2, yielded a lower number of MUs compared to plan 1
using PBC algorithm. Considering these results the use of
plan 2 instead of plan 1 to treat the patients would result in
under dosage to PTVs and a different dose distribution which
may be better for the OARs. This difference may have a
clinical impact compared to the reference plan. This overall
difference of 5% is the main result of this study. However,
different cancer sites should be considered individually be-
fore making any rule of dose modification.
Isocenter dose
The test algorithm in plan 3 calculated significantly higher
dose at the isocenter than the prescribed dose in plan 1 by on
average 5.2% (1.4 SD, p = 0.028) with CL = 7.9. This means
that using the MUs calculated for plan 1, in plan 3, produces a
delivered dose that is higher by about 5% than the dose pre-
scribed by the oncologist. For sites surrounded by paren-
chyma which have a very low density, from 0.2 to 0.4g/cm3,
the dose normalization method using MUs from plan 1 to
calculate the dose in plan 3 using test algorithm confirms that
the dose delivered was higher by 5% compared to the pre-
scribed dose using reference algorithm.
Considering that plan 2 (PBC-MB) is more realistic, because it
take into account the heterogeneity correction, we can give
the following example: if the oncologist’s prescription was
66Gy using reference algorithm, a dose higher by 5% (close to
69Gy) would have been “actually delivered” with the corre-
sponding clinical result. However, using PBC-MB, the on-
cologist’s prescription of 66Gy would “really” give 66Gy to
the patient, once again with the corresponding clinical result,
which may be expected to be reduced compared to that with
plan 1. So, using PBC-MB without modifying the prescribed
dose will result in a significantly lower effective dose deliv-
ered to the patient compared to that in the original plan using
reference algorithm. However, a lower dose to both PTVs and
OARs may result in an overall better outcome and may give a
better result according to the respective positions of tumor
control probability and normal tissues complication proba-
bility curves.19
Dose distribution in 2D and 3D
2D Gamma
The 2D gamma was calculated considering all pixels for all
patients using only the transverse plane through isocenter for
plan 1 and plan 2. The results for the 2D gamma show the
pixels where the gamma > 1 using the set criteria (3%, 3 mm)
in the comparison of the two algorithms. Comparing plan 1
and plan 2 for all patient (n = 6), the maximum gamma value
was 2.5, average gamma value of 0.3 (2.2 SD) and CL = 4.61,
depending on the site location. The maximum gamma value
(2.5) was observed for the parenchyma site. The gamma
evaluation shows that the difference in the dose between the
two algorithms could be as large as ±8% in low gradient high
dose areas.
Figure 3 (a) shows a sample of a gamma map in 2D in the
traverse plane from the comparison between the two algo-
rithms. This includes two PTVs located in a parenchyma
tumor using plan 1 and plan 2. The gamma map was calcu-
lated in 2D using DICOM images including the PTVs, healthy
lung and spinal cord. The red shading indicates that gamma
values were above unity (out of tolerance). Figure 3 (b),
shows the CT scan for the parenchyma site and the red circle
indicates the PTV2 and the yellow circle the PTV1. Each PTV
was treated using 3 fields. The comparison between the
gamma map (Figure 3 (a)) and the CT scan (Figure 3 (b)) is
obvious, it yields colored patches in red (gamma >1) located
in PTVs and OARs.
3D Gamma
The comparison between reference algorithm vs. test algo-
rithm using gamma (3%, 3 mm), showed in all patient cases
an under estimating dose for PTVs and over estimating dose
for OARs when plan 2 was used. There are also a significant
difference between both GVHs (Dt > Dr) and (Dt < Dr), p <
0.05. Figure 5 shows a sample of the 3D gamma map resulting
from the comparison between the two algorithms for a pa-
renchyma tumor combining plan 1 and plan 2. The results
shows that using test algorithm the dose for OARs was higher
(red coloring), but a fraction of the PTVs will be under dosage
(blue color) compared to reference algorithm.
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FIG. 3: A sample gamma map in 2D plotted on the transversal plane for comparing the test and reference algorithms in plan 1 and plan 2. The red
coloring in graph 3 (a) indicates that gamma values were > 1. The circle landmarks in Figure 3 (a) indicate the PTV contours around the isocenter
point in the transverse plane. On the right, Figure 3(b) shows the CT scan for the parenchyma site; the red circle shows PTV2 and the yellow
circle shows PTV1.
FIG. 4: The cumulative gamma pixel histograms in 2D obtained when comparing the two algorithms for the 6 fields used to irradiate PTV1 and
PTV2 located in the parenchyma site. We note that the gamma index criterion: 95% of pixels with gamma index ≤ 1 was not satisfied.
FIG. 5: A sample gamma map in 3D plotted in the transverse plane for comparing test and reference algorithms for the parenchyma site includ-
ing 6 fields. The red and blue coloring indicates that gamma is outside the tolerance with over or under estimation of the dose respectively.
Khaki coloring indicates the pixels with doses lower than 10% of the prescribed dose. Black coloring indicates the pixels outside the patient.
The circle landmarks in the figure indicate the PTVs contours around the isocenter point in the transverse plane.
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FIG 6: Cumulative GVHs in 3D obtained when comparing the two algorithms for 6 fields used for parenchyma site. It can be seen that 5% of
the voxels having  > 1, which indicates an over dosage. Conversely for the under dosage, 45% of the voxel have a ( < -1). This means that the
tolerance level, 95% of voxels having gamma ≤ 1, is not obtained using PBC-MB method for plan 2.
Figure 4 shows the gamma pixel histograms in 2D obtained
from the comparison between the two algorithms for 6 fields
used to irradiate the PTV1 and PTV2 located in the paren-
chyma site. In this case we can see that only 75% of pixels
have a gamma index ≤ 1 using (3%, 3 mm). The tolerance of
95% pixels with gamma≤ 1 was not satisfied.
Figure 6 shows the absolute values of the cumulative GVHs in
3D. The GVHs separate the total voxels into positive and
negative voxels for the comparison of both algorithm which
discriminate the under and over dosage regions. It can be seen
that 5% of the voxels having an over dosage ( > 1) deviates
from the tolerance, which reaches the level of 95%. Con-
versely for the under dosage voxels, 45% of the voxel have a
( < -1). It should be noted that this is a relative evaluation
within two groups of voxels (positives vs negatives) and does
not give absolute information. It must be estimated for the
spatial distribution of colored areas in Figure 5.
Discussion
2D and 3D gamma evaluations
In this paper we describe a method based on the gamma
function (2D and/or 3D) to evaluate the dose differences and
it is applied to a change from PBC with no density correction
to PBC with modified Batho’s method. The 2D and 3D gamma
analysis based on plan 1 and plan 2 for each patient using all
treatment fields. The gamma values reflect changes in the
relative dose distribution in the PTVs and OARs between
plan 1 and plan 2. In this study plan 2 and plan 3 were used to
carry out the quantitative evaluation. After the validation of
the newer algorithm in our department, the ICRU recom-
mendation, were used to validate plan 2. Plan 3 was only to
compare the prescribed dose. The gamma analysis showed a
disagreement between the two dose distributions.
The average value for gamma in 2D was less than 1 for all
patients in a given treatment plan, but the maximum can be
up to 2. The comparison of GVHs in 3D allows qualifying this
difference (under or over dosage) and demonstrated an un-
der-dosage using test algorithm compared to reference algo-
rithm. The importance of gamma maps is that showing the
location of area which does not respect the tolerance levels in
the CT-scan for the patient. The 3D gamma maps showed
underestimating dosage (blue color) located in the PTVs and
overestimating dosage for OARs (red coloring) for all pa-
tients. However to take into account the heterogeneity cor-
rection for lung, using (plan 2), the dose calculated to the
OARs located beyond the tumor will increase due to attenu-
ation correction. In this case the gamma index will fail but the
dose to the OARs will be closer to reality. This means that
using tolerance level (3%, 3 mm) for the gamma passing rate
showed a dose difference in critical anatomic region around
the PTVs, as showing in Figures 3 and 5. This is an alert for
the physicist and the oncologist that the gamma passing rate
for OARs is not satisfied (gamma >1). However in good prac-
tice the final verification using dose volume histogram (DVH)
allows to check the satisfaction of the protective constrains
for the OARs before the final validation of the treatment.
Chaikh et al showed that the PBC-MB calculated a higher
mean dose for normal lung, the dosimetric parameters de-
rived from DVH were higher 8% for OARs.20
Tolerance levels to compare dose calculation algo-
rithms in clinical use
As mentioned above, the first steps in the method in Figure 1
(determining the change in MUs, or the change in isocenter
dose with the new MUs) are standard methods that are rou-
tinely used. Then the second approach is the use of 2D and 3D
gamma maps and histograms. The comparison of dose calcu-
lation algorithms have one very important particularity, it is
that the dose difference is only related to the change of cal-
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culation method. This means, turning on the modified
Batho’s method, has not moved any beam edges, energy or
angle. It is interesting to note that, the average  values for all
patient (n = 6) were less than the unity when using a 2D
gamma evaluation with (3%, 3 mm) criterion. On a (3%, 3
mm) 2D gamma, all points would have a  < 1, and so the flow
chart on Figure 1 would conclude "no dose difference" alt-
hough we observed a prescriptions dose difference higher
than 3%. The histogram pixels gamma and GVHs presented in
Figures 4 and 6 showed that the 95% of pixels/voxels had < 1
not respected for all patient (n = 6). Similarly if a change in
algorithm made all beam edges move out by just under 3 mm,
this would again pass the 2D gamma, rather than alerting the
physicist to the very serious change. Whilst the gamma index
is a very useful tool for comparing measured and calculated
dose differences, in situations where the measurement un-
certainties introduce a mix of positional and dosimetric un-
certainties, its utility for comparing the results of two plan-
ning algorithms is less obvious. A better tool in this case
would be a simple dose difference map. A consideration of
how much of the area exceeds 1%, 2% or 3% would be a
better measure than the gamma index as used here (3%, 3
mm). Consequently, to compare dose calculation algorithms
for the same patient and the same configuration it would be
better to use more sensitive criteria for dose difference for
gamma evaluation. It is also possible to imagine some future
algorithm change that uniformly changes the dose at every
point by 2.99%. This could have very different consequences
according to the local level of dose since radiobiological re-
sponses follow sigmoid curves.19 We recommend that the
tolerance level to compare two algorithms should be adapted
and defined for clinical use for the various tests.
The need to adjust the prescribed dose in radiotherapy
Clinicians should not forget that the visualized dose distribu-
tions obtained from TPS are only approximate representa-
tions of the real dose distributions. Thus, when changing
from one algorithm to another in a radiation oncology de-
partment, modifications in the dose calculation must be
carefully identified. It has been recently suggested that there
is a need to adjust the prescribed dose of radiation especially
after the implementation of the Anisotropic Analytical Algo-
rithm (AAA) in the clinic.21 However, in our department this
question was raised with the transition from a Clarkson al-
gorithm to a PBC algorithm without heterogeneity correc-
tion.22 In fact the difference between MUs calculated using
the Clarkson algorithm and PBC without heterogeneity cor-
rection was less than 1% for lung sites with a SD smaller than
1%. Subsequently we investigated the transition from PBC
without heterogeneity correction (reference algorithm) to
PBC-MB (test algorithm). The differences found for very
heterogeneous volumes were then clearly larger, and truly
raised the question of an objective decision process to change
our prescription habit in order to maintain the same clinical
results.
Our comparison, based on 59 fields, demonstrated that the
calculated dose in MUs using the test algorithm was less than
with reference algorithm. On average, deviations as large as
5% exist between the two algorithms. The differences in MUs
were influenced by the field size, the anatomical structures
surrounding the lung and the beam intensity. Thus, for beams
with a long path through the lung the difference in MUs was
increased. A statistical evaluation based on Wilcoxon’s test
showed that this difference between MUs was significant.
The deviations between the two algorithms were very sig-
nificant for cancer located in lung parenchyma. The signifi-
cant difference in MUs reflects the under-dosage observed in
3D gamma when test algorithm was used. Consequently, the
risk due to the change in the algorithm from PBC to PBC-MB
was a reduction in the dose delivered in MUs to the PTVs.
Therefore, when changing from algorithm PBC to PBC-MB, a
routine adjustment of the prescription made by the radiation
oncologists appears necessary. In terms of the results found in
the present study, this adjustment could be an increase of
+5% in the prescribed dose in Gy, in order to continue to
deliver the same actual dose to the tumor as when using the
reference algorithm.
Instead of deciding to alter our prescription habits according
to a certain level of difference in dose, it appeared to us more
reliable to statistically ascertain the observed differences. The
choice of an alpha risk of 5% appeared natural to us as it is
used for almost all the statistical decisions in medi-
co-biological sciences. Therefore we recommend testing and
evaluating the new calculation algorithms for different ana-
tomical sites and especially those where strong differences in
tissue densities exist, as in thoracic locations. These results, if
significant, should be discussed among clinicians and medical
physicists to decide whether or not an alteration of the cur-
rent prescription procedure should be considered.
Limits of this study
The main limitation of this study was the number of patients.
However, the use of the Wilcoxon's test allowed us to calcu-
late p-values for a small population size.17 In fact, the com-
parison of PBC and PBC-MB algorithms doesn’t give the
present state of the art. For example, there is more accurate
algorithm such as AAA and Collapsed Cone Convolution
superposition algorithm.23, 24, 25, 26 But, the PBC with and
without heterogeneity corrections were available algorithms
in our department. These algorithms were simply used as an
example to show the application of a new comparative tech-
nique and to validate our method. However, this method is
general and can be used to compare any other algorithm in
present and future practice.
The confidence limit is based on the average deviation be-
tween dose calculation using the reference and test algorithm
and the SD. The multiplicative factor of 1.96 has been pro-
posed by Palta et al.18 for having 5% of the individual points
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exceeding the tolerance level. In this study we observed
higher values to CL related to higher values for SD. The large
standard deviations for ∆MUs and ∆Dose at the isocenter are
due to the heterogeneity of our population. Further studies
that include patients presenting the same type of tumor site
could certainly refine our conclusions.
A comparison of MUs proved to be useful for the first step
comparison of algorithms. However the comparison of two
different techniques of treatment is not possible by only
comparing MUs since other parameters change besides the
calculation method. For this reason, the 2D or 3D gamma
analysis methods are convenient to compare techniques (i.e.,
IMRT or VMAT vs RT3D) since they just require DICOM
files of two dose distributions, whatever their origins, for the
two treatment plans and do not need the MUs. Moreover, the
3D gamma analysis shows the over or under estimation dose
areas. However, 3D gamma takes much longer to carry out
than 2D gamma. To accelerate the 3D gamma calculation the
low dose levels, for instance below 10%, could be eliminated
from the comparison.16 The gamma evaluation could have
false positive and or negative and the common criterion (3%,
3 mm) is insufficient for patient IMRT quality assurance.27, 28
Conclusion
In this study we introduced a global method based on MUs
and gamma evaluation in 2D and 3D to adjust the prescribed
dose in radiotherapy. This method enables physicians and the
oncologists to be aware of treatment modifications associated
with a change in dose calculation software. The 2D and 3D
gamma evaluation confirms the under dosage observed with
PBC-MB using MUs comparison. For lung tumors, according
to this study, the prescribed dose had to be adjusted by 5%
when moving from PBC algorithm to PBC-MB in order to
obtain the same delivered dose in the PTVs and the same
clinical results as for the former reference treatment plan.
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